FindTrial
Sign In

Evaluation of the Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell Lymphoma

Evaluation of the Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell Lymphoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600127315
Enrollment
Unknown
Registered
2026-06-29
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous T-cell lymphoma

Interventions

Placebo group:A placebo composed of the base ingredients of Benvitimod cream, apply the area of two palms per fingertip unit, once a day
Trial group:Benvitimod Cream (Zelimei), apply the area of two palms per fingertip unit, once a day

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients diagnosed with cutaneous T-cell lymphoma (CTCL) by skin biopsy; 2.Aged 18 years or older; 3.Possess complete clinical data; 4.Voluntarily participate in this study; 5.Good compliance with treatment; 6.Willing to attend follow-up visits; 7.Conscious, with no cognitive impairment or communication barriers;

Exclusion criteria

Exclusion criteria: 1.Pregnant or lactating women, or those planning pregnancy within 6 months; 2.Unwilling to sign the informed consent form (ICF); 3.Allergic (or hypersensitive) to benvitimod cream;

Design outcomes

Primary

MeasureTime frame
Improvement in skin lesions and pruritus;—

Secondary

MeasureTime frame
Incidence of adverse events (AEs) and adverse drug reactions (ADRs);—

Countries

China

Contacts

Public ContactWang Yang

Peking University First Hospital

yangwang_dr@bjmu.edu.cn+86 10 83573273

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026